Inactivated Polio Vaccine (IPV): A strong candidate vaccine for achieving global polio eradication program

Vaccine ◽  
2009 ◽  
Vol 27 (39) ◽  
pp. 5293-5294 ◽  
Author(s):  
Aamir Shahzad ◽  
Gottfried Köhler
2018 ◽  
Vol 67 (suppl_1) ◽  
pp. S57-S65 ◽  
Author(s):  
James T Gaensbauer ◽  
Chris Gast ◽  
Ananda S Bandyopadhyay ◽  
Miguel O’Ryan ◽  
Xavier Saez-Llorens ◽  
...  

PLoS ONE ◽  
2013 ◽  
Vol 8 (12) ◽  
pp. e83374 ◽  
Author(s):  
Yvonne E. Thomassen ◽  
Aart G. van ’t Oever ◽  
Monique G. C. T. van Oijen ◽  
René H. Wijffels ◽  
Leo A. van der Pol ◽  
...  

2021 ◽  
Vol 308 ◽  
pp. 02018
Author(s):  
Yushuo Chen ◽  
Tianrui Yue ◽  
Zixiao Zhang

Poliomyelitis is an exclusively human disease that mainly affects children. Clinical features of poliomyelitis can be varied, from mild illness to the most severe paralysis, and the factor why poliomyelitis has different performances in individuals has been proved strongly correlated with membrane protein CD155. The nervous system shows a special protecting phenomenon against the invasion of poliovirus, and the mechanism is not very clear at present. Vaccines are the main means of preventing and controlling polio, and many different vaccines have been invented in the process of fighting polio. Inactivated polio vaccine (IPV) and oral polio vaccine (OPV) are the two main vaccines. IPV is known for its safety while OPV is widely used in developing countries because of its relatively low cost. This usage also leads to some side effects: vaccine-associated paralytic polio (VAPP) and vaccine-derived poliovirus (VDPV). Now, for polio eradication, the elimination of these two diseases has become particularly important. Thus, a new type of vaccine was created: sequential IPV-OPV with the safety of IPV and the low cost of OPV. This paper will talk about the different polio vaccines and their effects. An enormous difference between people who have gotten the vaccine and people who have not got the vaccine. Comparing the two kinds of people, people who get normal poliovirus, and people who get poliovirus after taking a vaccine, known as VAPP (vaccine-associated paralytic poliomyelitis), the former cannot get full recovery whole life and the latter has a very low possibility. In conclusion, people should take vaccines if it is affordable for them.


2017 ◽  
Vol 41 ◽  
pp. 1
Author(s):  
Cristina Pedreira ◽  
Elizabeth Thrush ◽  
Gloria Rey-Benito ◽  
Ana Elena Chévez ◽  
Barbara Jauregui

This article synthesizes the important lessons learned from polio eradication in the Region of the Americas, including initial and more recent challenges and best practices, as well as particular factors surrounding attainment of this ambitious goal. Using documents, interviews, and country surveys, the authors describe and analyze the strategies and lessons learned during the 40 years of the Expanded Program on Immunization (1977 – 2017). Some major milestones and chxallenges specifically covered are: the Vaccine-derived Poliovirus (VDPV) outbreak in the Dominican Republic; the regional “mop-up operation;” poliovirus containment in essential facilities; the unprecedented introduction of inactivated polio vaccine (IPV); the synchronized switch from trivalent to bivalent OPV; and the countries’ unfailing commitment to the cause.


2017 ◽  
Vol 24 (06) ◽  
pp. 919-923
Author(s):  
NAILA AZAM ◽  
SHAMAILA MOHSIN ◽  
AAMIRA HASHMI ◽  
MUHAMMAD IMRAN ◽  
FARMAN ALI ◽  
...  

2019 ◽  
Vol 31 (1) ◽  
pp. 22-28 ◽  
Author(s):  
Kazi Zulfiquer Mamun ◽  
Nabeela Mahboob ◽  
Kazi Taib Mamun ◽  
Hasina Iqbal

Oral polio vaccine (OPV) has served as the cornerstone of polio eradication efforts over the past 30 years, trivalent inactivated polio vaccine (IPV) has re-ascended to prominence in the past year, now acting as the sole source of protective immunity against type 2 poliovirus in routine immunization programmes. The Polio Eradication and Endgame Strategic plan 2013–2018, developed by the Global Polio Eradication Initiative (GPEI) outlines the phased removal of OPVs, starting with type 2 poliovirus–containing vaccines and introduction of inactivated polio vaccine in routine immunization to mitigate against risk of vaccine-associated paralytic polio and circulating vaccine-derived poliovirus. Bangladesh J Medicine Jan 2020; 31(1) : 22-28


PEDIATRICS ◽  
2016 ◽  
Vol 137 (Supplement 3) ◽  
pp. 389A-389A
Author(s):  
Oluyemisi O. Falope ◽  
Korede K. Adegoke ◽  
Chukwudi O. Ejiofor ◽  
Nnadozie C. Emechebe ◽  
Taiwo O Talabi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document